The Association between Immune Checkpoint Proteins and Therapy Outcomes in Acute Myeloid Leukaemia Patients

SIMPLE SUMMARY: Despite promising results of clinical trials, the use of immune checkpoint inhibitors (ICI) in acute myeloid leukaemia (AML) remains limited. To date, the United States Food and Drug Administration (FDA) has approved two PD-1 inhibitors, namely nivolumab and pembrolizumab, for treati...

Descripción completa

Detalles Bibliográficos
Autores principales: Bolkun, Lukasz, Tynecka, Marlena, Walewska, Alicja, Bernatowicz, Malgorzata, Piszcz, Jaroslaw, Cichocka, Edyta, Wandtke, Tomasz, Czemerska, Magdalena, Wierzbowska, Agnieszka, Moniuszko, Marcin, Grubczak, Kamil, Eljaszewicz, Andrzej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526931/
https://www.ncbi.nlm.nih.gov/pubmed/37760457
http://dx.doi.org/10.3390/cancers15184487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526931/
https://www.ncbi.nlm.nih.gov/pubmed/37760457
http://dx.doi.org/10.3390/cancers15184487

Ejemplares similares